Logo image of IFRX

INFLARX NV (IFRX) Stock Price, Quote, News and Overview

NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD

0.8099  +0.04 (+5.18%)

IFRX Quote, Performance and Key Statistics

INFLARX NV

NASDAQ:IFRX (6/18/2025, 11:11:11 AM)

0.8099

+0.04 (+5.18%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.82
52 Week Low0.71
Market Cap54.37M
Shares67.13M
Float62.81M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/bmo
IPO11-16 2017-11-16


IFRX short term performance overview.The bars show the price performance of IFRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

IFRX long term performance overview.The bars show the price performance of IFRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IFRX is 0.8099 USD. In the past month the price decreased by -56.5%. In the past year, price decreased by -50.01%.

INFLARX NV / IFRX Daily stock chart

IFRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.79B
AMGN AMGEN INC 13.96 155.81B
GILD GILEAD SCIENCES INC 13.98 134.60B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.76B
REGN REGENERON PHARMACEUTICALS 11.64 55.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 41.17B
ARGX ARGENX SE - ADR 94.63 33.22B
ONC BEONE MEDICINES LTD-ADR 6.56 27.72B
BNTX BIONTECH SE-ADR N/A 25.21B
NTRA NATERA INC N/A 23.17B
BIIB BIOGEN INC 8.05 18.67B
INSM INSMED INC N/A 18.35B

About IFRX

Company Profile

IFRX logo image InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Company Info

INFLARX NV

Winzerlaer Str. 2

Jena THUERINGEN 07745 DE

CEO: Niels Riedemann

Employees: 74

IFRX Company Website

IFRX Investor Relations

Phone: 493641508180

INFLARX NV / IFRX FAQ

What is the stock price of INFLARX NV today?

The current stock price of IFRX is 0.8099 USD. The price increased by 5.18% in the last trading session.


What is the ticker symbol for INFLARX NV stock?

The exchange symbol of INFLARX NV is IFRX and it is listed on the Nasdaq exchange.


On which exchange is IFRX stock listed?

IFRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INFLARX NV stock?

14 analysts have analysed IFRX and the average price target is 5.39 USD. This implies a price increase of 565.69% is expected in the next year compared to the current price of 0.8099. Check the INFLARX NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INFLARX NV worth?

INFLARX NV (IFRX) has a market capitalization of 54.37M USD. This makes IFRX a Micro Cap stock.


How many employees does INFLARX NV have?

INFLARX NV (IFRX) currently has 74 employees.


What are the support and resistance levels for INFLARX NV (IFRX) stock?

INFLARX NV (IFRX) has a resistance level at 1.85. Check the full technical report for a detailed analysis of IFRX support and resistance levels.


Is INFLARX NV (IFRX) expected to grow?

The Revenue of INFLARX NV (IFRX) is expected to decline by -45.24% in the next year. Check the estimates tab for more information on the IFRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INFLARX NV (IFRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INFLARX NV (IFRX) stock pay dividends?

IFRX does not pay a dividend.


When does INFLARX NV (IFRX) report earnings?

INFLARX NV (IFRX) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of INFLARX NV (IFRX)?

INFLARX NV (IFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).


What is the Short Interest ratio of INFLARX NV (IFRX) stock?

The outstanding short interest for INFLARX NV (IFRX) is 2.02% of its float. Check the ownership tab for more information on the IFRX short interest.


IFRX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IFRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IFRX. IFRX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IFRX Financial Highlights

Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS decreased by -5.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -51.4%
ROE -63.47%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%23.53%
Sales Q2Q%-100%
EPS 1Y (TTM)-5.63%
Revenue 1Y (TTM)31.38%

IFRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to IFRX. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 0.37% and a revenue growth -45.24% for IFRX


Ownership
Inst Owners26.24%
Ins Owners6.43%
Short Float %2.02%
Short Ratio2.46
Analysts
Analysts84.29
Price Target5.39 (565.51%)
EPS Next Y0.37%
Revenue Next Year-45.24%